ProBioGen partners with Granite Bio for cell line development and GMP manufacturing services
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
Evonik's six innovation growth fields are: Sustainable nutrition, healthcare solutions, advanced food ingredients, membranes, cosmetic solutions, and additive manufacturing
Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.
Brings 25 years of global operations and supply chain experience to Piramal
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Ultomiris showed early effect and lasting improvement in activities of daily living and has potential to reduce treatment burden with dosing every 8 weeks
In this role, Romanelli will have P&L responsibility for Merck’s US $22 billion international human health business and lead a team of 14,000 colleagues in more than 75 markets outside of the U.S
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
Subscribe To Our Newsletter & Stay Updated